S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
S&P 500   4,277.67 (-0.25%)
DOW   33,371.75 (-0.18%)
QQQ   359.49 (-0.49%)
AAPL   173.21 (-0.31%)
MSFT   319.93 (-0.58%)
META   304.82 (-0.65%)
GOOGL   133.33 (-0.63%)
AMZN   127.14 (-1.79%)
TSLA   247.61 (-1.59%)
NVDA   447.39 (-0.10%)
NIO   8.56 (-2.62%)
BABA   84.41 (-2.45%)
AMD   102.10 (-1.13%)
T   14.71 (+0.27%)
F   12.14 (-1.38%)
MU   68.63 (+0.99%)
CGC   0.72 (-2.97%)
GE   109.62 (+0.76%)
DIS   80.97 (-0.86%)
AMC   8.06 (-1.10%)
PFE   33.92 (-0.06%)
PYPL   58.20 (-0.61%)
NFLX   377.02 (-0.87%)
NASDAQ:MORF

Morphic (MORF) Stock Forecast, Price & News

$21.73
+0.72 (+3.43%)
(As of 09:46 AM ET)
Compare
Today's Range
$21.26
$21.77
50-Day Range
$21.01
$59.22
52-Week Range
$19.80
$63.08
Volume
120,602 shs
Average Volume
608,131 shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.71

Morphic MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
193.7% Upside
$61.71 Price Target
Short Interest
Bearish
6.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
-0.04mentions of Morphic in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.50 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.83) to ($4.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

423rd out of 975 stocks

Pharmaceutical Preparations Industry

181st out of 455 stocks


MORF stock logo

About Morphic (NASDAQ:MORF) Stock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

MORF Price History

MORF Stock News Headlines

Morphic (NASDAQ:MORF) Shares Up 7.6%
Where Morphic Holding Stands With Analysts
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
BMO Capital Markets Cuts Morphic (NASDAQ:MORF) Price Target to $52.00
Morphic (NASDAQ:MORF) Stock Price Down 3.8% After Analyst Downgrade
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Morphic (NASDAQ:MORF) Downgraded by BTIG Research to "Neutral"
BTIG Downgrades Morphic Holding (MORF)
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Morphic (NASDAQ:MORF) Stock Price Down 5.4%
Morphic (NASDAQ: MORF)
See More Headlines
Receive MORF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter.

MORF Company Calendar

Last Earnings
8/03/2023
Today
10/03/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MORF
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$61.71
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+193.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-59,040,000.00
Pretax Margin
-1,484.46%

Debt

Sales & Book Value

Annual Sales
$70.81 million
Book Value
$9.06 per share

Miscellaneous

Free Float
34,457,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.33
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Praveen P. Tipirneni M.D. (Age 55)
    CEO, MD & Director
    Comp: $991.33k
  • Dr. Bruce N. Rogers Ph.D. (Age 54)
    Pres
    Comp: $787.88k
  • Dr. Timothy A. Springer Ph.D. (Age 75)
    Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $40k
  • Dr. Marc Schegerin M.B.A. (Age 47)
    M.D., CFO & COO
    Comp: $722.38k
  • Mr. Robert E. Farrell Jr.Mr. Robert E. Farrell Jr. (Age 58)
    CPA, CPA, Sr. VP of Fin. & Chief Accounting Officer
  • Dr. Blaise Lippa Ph.D.
    Chief Scientific Officer
  • Mr. William D. DeVaul Esq. (Age 52)
    Gen. Counsel & Sec.
  • Mr. Aaron Pelta
    Sr. VP of Bus. & Corp. Devel.
  • Ms. Joanne Gibbons
    Sr. VP of Regulatory Affairs













MORF Stock - Frequently Asked Questions

Should I buy or sell Morphic stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares.
View MORF analyst ratings
or view top-rated stocks.

What is Morphic's stock price forecast for 2023?

7 analysts have issued 1-year price objectives for Morphic's shares. Their MORF share price forecasts range from $33.00 to $80.00. On average, they predict the company's share price to reach $61.71 in the next year. This suggests a possible upside of 193.7% from the stock's current price.
View analysts price targets for MORF
or view top-rated stocks among Wall Street analysts.

How have MORF shares performed in 2023?

Morphic's stock was trading at $26.75 at the beginning of the year. Since then, MORF stock has decreased by 21.5% and is now trading at $21.01.
View the best growth stocks for 2023 here
.

When is Morphic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MORF earnings forecast
.

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.02. Morphic had a negative trailing twelve-month return on equity of 27.71% and a negative net margin of 92.38%.

What other stocks do shareholders of Morphic own?
When did Morphic IPO?

(MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

What is Morphic's stock symbol?

Morphic trades on the NASDAQ under the ticker symbol "MORF."

How do I buy shares of Morphic?

Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Morphic's stock price today?

One share of MORF stock can currently be purchased for approximately $21.01.

How much money does Morphic make?

Morphic (NASDAQ:MORF) has a market capitalization of $1.01 billion and generates $70.81 million in revenue each year. The company earns $-59,040,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Morphic have?

The company employs 110 workers across the globe.

How can I contact Morphic?

Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The official website for the company is www.morphictx.com. The company can be reached via phone at (781) 996-0955.

This page (NASDAQ:MORF) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -